Movement Alert｜Celcuity Inc Declines 5.45% Overnight, Classic Sell-the-News Pattern Following FDA Approval of Core Drug REVTORPYK

Market Focus07-15

On July 15, Celcuity Inc fell 5.45% overnight, trading at $105.0/share, with turnover of $4,229.8. The decline followed FDA formal approval of the company's core drug REVTORPYK for HR+/HER2-negative, PIK3CA wild-type locally advanced or metastatic breast cancer.

The approval was based on the Phase 3 VIKTORIA-1 trial, in which median progression-free survival reached 9.3 months with the REVTORPYK triplet combination versus 2.0 months with fulvestrant alone. However, the stock had already surged over 5% intraday ahead of the approval as the PDUFA target date of July 17 approached, prompting a typical profit-taking selloff once the positive catalyst materialized.

Additionally, the current approval covers only PIK3CA wild-type patients. A supplemental application for the PIK3CA-mutated population is expected to be submitted in the third quarter, creating a potential expectation gap regarding the breadth of the approved indication. Celcuity plans a commercial launch in late third quarter.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1132053662?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 08:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132053662","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Celcuity Inc Declines 5.45% Overnight, Classic Sell-the-News Pattern Following FDA Approval of Core Drug REVTORPYK","media":"Market Focus","content":"<p><p>On July 15, Celcuity Inc fell 5.45% overnight, trading at $105.0/share, with turnover of $4,229.8. The decline followed FDA formal approval of the company's core drug REVTORPYK for HR+/HER2-negative, PIK3CA wild-type locally advanced or metastatic breast cancer.</p><p>The approval was based on the Phase 3 VIKTORIA-1 trial, in which median progression-free survival reached 9.3 months with the REVTORPYK triplet combination versus 2.0 months with fulvestrant alone. However, the stock had already surged over 5% intraday ahead of the approval as the PDUFA target date of July 17 approached, prompting a typical profit-taking selloff once the positive catalyst materialized.</p><p>Additionally, the current approval covers only PIK3CA wild-type patients. A supplemental application for the PIK3CA-mutated population is expected to be submitted in the third quarter, creating a potential expectation gap regarding the breadth of the approved indication. Celcuity plans a commercial launch in late third quarter.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Celcuity Inc Declines 5.45% Overnight, Classic Sell-the-News Pattern Following FDA Approval of Core Drug REVTORPYK</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Celcuity Inc Declines 5.45% Overnight, Classic Sell-the-News Pattern Following FDA Approval of Core Drug REVTORPYK\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-15 08:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 15, Celcuity Inc fell 5.45% overnight, trading at $105.0/share, with turnover of $4,229.8. The decline followed FDA formal approval of the company's core drug REVTORPYK for HR+/HER2-negative, PIK3CA wild-type locally advanced or metastatic breast cancer.</p><p>The approval was based on the Phase 3 VIKTORIA-1 trial, in which median progression-free survival reached 9.3 months with the REVTORPYK triplet combination versus 2.0 months with fulvestrant alone. However, the stock had already surged over 5% intraday ahead of the approval as the PDUFA target date of July 17 approached, prompting a typical profit-taking selloff once the positive catalyst materialized.</p><p>Additionally, the current approval covers only PIK3CA wild-type patients. A supplemental application for the PIK3CA-mutated population is expected to be submitted in the third quarter, creating a potential expectation gap regarding the breadth of the approved indication. Celcuity plans a commercial launch in late third quarter.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CELC","symbol_name":"Celcuity Inc","start_time":0,"source_url":"","article_id":"1132053662","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132053662","pubTimestamp":1784075599,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 15, Celcuity Inc fell 5.45% overnight, trading at $105.0/share, with turnover of $4,229.8. The decline followed FDA formal approval of the company's core drug REVTORPYK for HR+/HER2-negative,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CELC":"Celcuity Inc"},"translate_title":"走势警报|Celcuity Inc 隔夜下跌 5.45%，核心药物 REVTORPYK 获得 FDA 批准后经典的新闻抛售模式","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CELC":1},"content_text":"On July 15, Celcuity Inc fell 5.45% overnight, trading at $105.0/share, with turnover of $4,229.8. The decline followed FDA formal approval of the company's core drug REVTORPYK for HR+/HER2-negative, PIK3CA wild-type locally advanced or metastatic breast cancer.The approval was based on the Phase 3 VIKTORIA-1 trial, in which median progression-free survival reached 9.3 months with the REVTORPYK triplet combination versus 2.0 months with fulvestrant alone. However, the stock had already surged over 5% intraday ahead of the approval as the PDUFA target date of July 17 approached, prompting a typical profit-taking selloff once the positive catalyst materialized.Additionally, the current approval covers only PIK3CA wild-type patients. A supplemental application for the PIK3CA-mutated population is expected to be submitted in the third quarter, creating a potential expectation gap regarding the breadth of the approved indication. Celcuity plans a commercial launch in late third quarter.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132053662","isCrawlerRequest":true}